Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q2 2026
Holdings as of Jun 30, 2026, filed Aug 14, 2026. Long positions only; changes compare share counts with Q1 2026.
- Positions
- 37
- −2 vs. Q1 2026
- Portfolio value
- $424.4M
- +$16.2M (+4.0%) vs. Q1 2026
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| PMNProMIS Neurosciences Inc. | COM SHS | 86,150 | $1.13M | 0.3% | −285,252−76.8% | Reduced | History |
| DBVTDBV Technologies S.A. | SPONSORED ADS | 156,906 | $2.57M | 0.6% | +156,906 | New | History |
| RNTXRein Therapeutics, Inc. | COM NEW | 2,575,000 | $2.68M | 0.6% | +2,575,000 | New | History |
| HUMAHumacyte, Inc. | COM | 3,750,000 | $2.93M | 0.7% | 00.0% | Unchanged | History |
| ELVNEnliven Therapeutics, Inc. | COM | 70,000 | $3.55M | 0.8% | +70,000 | New | History |
| SCYXScynexis Inc | COM | 944,292 | $3.84M | 0.9% | 00.0% | UnchangedConverted for a 1-for-8 split | History |
| EVMNEvommune, Inc. | COM SHS | 325,000 | $4.32M | 1.0% | 00.0% | Unchanged | History |
| PALIPalisade Bio, Inc. | COM | 2,284,819 | $4.78M | 1.1% | −1,120,938−32.9% | Reduced | History |
| SLNSilence Therapeutics plc | ADS | 450,000 | $4.94M | 1.2% | −570,489−55.9% | Reduced | History |
| RZLTRezolute, Inc. | COM NEW | 951,809 | $4.95M | 1.2% | 00.0% | Unchanged | History |
| AMANAmanat Acquisition Corp. | CL A ORD | 500,000 | $5.08M | 1.2% | +500,000 | New | History |
| ALTAltimmune, Inc. | COM NEW | 1,741,232 | $5.29M | 1.2% | +1,741,232 | New | History |
| CGEMCullinan Therapeutics, Inc. | COM | 300,000 | $5.46M | 1.3% | 00.0% | Unchanged | History |
| JATTJATT II Acquisition Corp. | ORD SHS | 500,000 | $5.68M | 1.3% | +500,000 | New | History |
| RLMDRelmada Therapeutics, Inc. | COM | 842,106 | $5.83M | 1.4% | 00.0% | Unchanged | History |
| IFRXInflaRx N.V. | COM | 3,046,557 | $6.82M | 1.6% | +3,046,557 | New | History |
| DRUGBright Minds Biosciences Inc. | COM NEW | 109,603 | $7.69M | 1.8% | −110,397−50.2% | Reduced | History |
| EPRXEupraxia Pharmaceuticals Inc. | COM | 1,200,000 | $7.93M | 1.9% | 00.0% | Unchanged | History |
| IRDOpus Genetics, Inc. | COM | 1,970,187 | $8.10M | 1.9% | +1,645,847+507.4% | Added | History |
| LBRXLB Pharmaceuticals Inc | COM SHS | 317,221 | $10.3M | 2.4% | +17,221+5.7% | Added | History |
| NGNENeurogene Inc. | COM | 352,180 | $11.1M | 2.6% | −147,820−29.6% | Reduced | History |
| NKTRNektar Therapeutics | COM NEW | 175,000 | $12.2M | 2.9% | −141,453−44.7% | Reduced | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 700,000 | $12.6M | 3.0% | −1,050,000−60.0% | Reduced | History |
| CLYMClimb Bio, Inc. | COM | 1,000,000 | $13.0M | 3.1% | −334,130−25.0% | Reduced | History |
| IMMXImmix Biopharma, Inc. | COM | 1,277,642 | $13.2M | 3.1% | +927,642+265.0% | Added | History |
| CTNMContineum Therapeutics, Inc. | CL A | 921,481 | $15.1M | 3.6% | +121,283+15.2% | Added | History |
| SGMTSagimet Biosciences Inc. | COM SER A | 2,029,933 | $15.7M | 3.7% | +2,029,933 | New | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 855,813 | $16.7M | 3.9% | +355,813+71.2% | Added | History |
| ORKAOruka Therapeutics, Inc. | COM | 183,330 | $17.4M | 4.1% | 00.0% | Unchanged | History |
| ANNXAnnexon, Inc. | COM | 3,500,000 | $20.0M | 4.7% | +1,000,000+40.0% | Added | History |
| DFTXDefinium Therapeutics, Inc. | COM SHS | 425,000 | $20.0M | 4.7% | +425,000 | New | History |
| SLGLSol-Gel Technologies Ltd. | SHS NEW | 274,363 | $20.3M | 4.8% | 00.0% | Unchanged | History |
| ALMSAlumis Inc. | COM | 856,061 | $24.1M | 5.7% | 00.0% | Unchanged | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 4,215,930 | $24.9M | 5.9% | 00.0% | Unchanged | History |
| VERAVera Therapeutics, Inc. | CL A | 600,836 | $25.8M | 6.1% | +401,488+201.4% | Added | History |
| ABVXAbivax S.A. | SPONSORED ADS | 204,314 | $27.2M | 6.4% | +204,314 | New | History |
| VORVor Biopharma Inc. | COM NEW | 1,700,000 | $31.3M | 7.4% | −50,000−2.9% | Reduced | History |
Options (5)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q1 2026 (12)
Positions held at the end of Q1 2026 that are gone from this filing.
| Security | Class | Shares in Q1 2026 | Value in Q1 2026 | % of portfolio in Q1 2026 | History |
|---|---|---|---|---|---|
| APGEApogee Therapeutics, Inc. | COM | 374,000 | $31.5M | 7.7% | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 675,000 | $13.6M | 3.3% | History |
| IMVTImmunovant, Inc. | COM | 545,625 | $13.6M | 3.3% | History |
| JBIOJade Biosciences, Inc. | COM NEW | 964,462 | $13.6M | 3.3% | History |
| ZBIOZenas BioPharma, Inc. | COM | 524,066 | $10.2M | 2.5% | History |
| CMPXCompass Therapeutics, Inc. | COM | 1,350,000 | $7.14M | 1.7% | History |
| CNTXContext Therapeutics Inc. | COM | 2,238,496 | $5.86M | 1.4% | History |
| UNCYUnicycive Therapeutics, Inc. | COM NEW | 796,558 | $5.24M | 1.3% | History |
| TENXTenax Therapeutics, Inc. | COM NEW | 327,307 | $5.23M | 1.3% | History |
| PHVSPharvaris N.V. | COM | 82,800 | $2.34M | 0.6% | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 124,666 | $1.86M | 0.5% | History |
| ALKSAlkermes plc. | SHS | 50,000 | $1.77M | 0.4% | History |